TITLE

Case history: Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors

AUTHOR(S)
Tobert, Jonathan A.
PUB. DATE
July 2003
SOURCE
Nature Reviews Drug Discovery;Jul2003, Vol. 2 Issue 7, p517
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
In the 1950s and 1960s, it became apparent that elevated concentrations of plasma cholesterol were a major risk factor for the development of coronary heart disease, which led to the search for drugs that could reduce plasma cholesterol. One possibility was to reduce cholesterol biosynthesis, and the rate-limiting enzyme in the cholesterol biosynthetic pathway, 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase, was a natural target. Here, I describe the discovery and development of lovastatin - the first approved inhibitor of HMG-CoA reductase - and the clinical trials that have provided the evidence for the ability of drugs in this class to reduce the morbidity and mortality associated with cardiovascular disease.
ACCESSION #
10068377

 

Related Articles

  • PCSK9 inhibitors poised for breakthrough as new cholesterol-lowering therapy. Dellapena, Deb // Cardiology Today;Apr2013, Vol. 16 Issue 4, p1 

    The article discusses research on the development of drugs that inhibit proprotein convertase subtilisin/kexin type 9 or PCSK9 as an alternative to statins for lowering cholesterol, drawing attention at the 2013 American College of Cardiology Scientific Sessions among other cardiology conferences.

  • Pharmaceuticals: A new grammar for drug discovery. Fishman, Mark C.; Porter, Jeffery A. // Nature;9/22/2005, Vol. 437 Issue 7058, p491 

    Focuses on the potential of the genome to identify candidate drugs for development. Discovery of statins as agents that lower cholesterol levels in the bloodstream; Details on the number of distinct signaling pathways recognized in human cells; Link between disease and signaling pathways.

  • New drugs. Pennachio, Dorothy L. // Patient Care;Oct2003, Vol. 37 Issue 10, p18 

    Provides information on drug developments. Adverse effects of etanercept in patients with active ankylosing spondylitis; Dosage of rosuvastatin administered to patients with low density lipoprotein levels; Side effects of vardenafil in patients with erectile dysfunction.

  • Stroke as a Target in Medicinal Chemistry and Drug Discovery. Tuttolomondo, Antonino // Current Topics in Medicinal Chemistry;Oct2009, Vol. 9 Issue 14, p1237 

    The author dicusses stroke as a target in medicinal chemistry and discovery of drugs as of 2009. He cites the limited treatment options for ischemic stroke (IS) that are currently available. Also mentioned are the possible therapeutic targets in acute stroke treatment, including neuron damage...

  • Future Challenges for Microsomal Transport Protein Inhibitors. Wierzbicki, Anthony S. // Current Vascular Pharmacology;Jul2009, Vol. 7 Issue 3, p277 

    Atherosclerosis is a leading cause of morbidity and mortality worldwide. Statins are established as first choice drugs for the management of hyperlipidaemia and cardiovascular risk. However, a residual cardiovascular risk, partially attributable to lipids, remains even after statin treatment....

  • Rethinking Treatments For the Heart. Gorman, Christine // Time International (South Pacific Edition);1/15/2001, Issue 2, p63 

    Discusses the development of drugs for the treatment of heart diseases. Use of surgery to treat heart disease; Use of the human genome to develop drugs; How men and women at risk for heart disease will be identified at earlier stages of their condition; How drugs known as statins, can curb the...

  • New Cholesterol Medications Offer an Alternative to Statins.  // Healthy Years;Aug2013, Vol. 10 Issue 8, p4 

    The article announces the development of a new class of medication that reduce low-density lipoprotein (LDL) cholesterol levels to help patients who do not tolerate statins. It describes the new agents as monoclonal antibodies that bind to a protein known as PCSK9, which is involved in the...

  • Rethinking Treatments For the Heart. Gorman, Christine // Time;1/15/2001, Vol. 157 Issue 2, p85 

    Discusses the development of drugs for the treatment of heart diseases. Use of surgery to treat heart disease; Use of the human genome to develop drugs; How men and women at risk for heart disease will be identified at earlier stages of their condition; How drugs known as statins, can curb the...

  • Statins king of the pharmaceutical hill, but for how long? Johnsen, Michael // Drug Store News;1/19/2004, Vol. 26 Issue 1, p32 

    Reports on the development of several drugs offering alternative action to statins in the U.S. Citation of the popularity of statin drugs in the market; Discovery of ET-216, a compound capable of reversing plaque buildup within arteries by increasing high-density lipoprotein (HDL) levels;...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics